Fortunately, Dave’s wife knew an oncologist who had practiced at Emory Healthcare and was also the chief medical officer of the American Cancer Society. “He knew everybody and everything, really, about cancer and not just in the United States, but around the world,” says Dave.
Together Dave and his oncologist friend ticked down the list of potential types of primary cancers that could be causing the spread of cancer to Dave’s bones. Prostate cancer would be a likely culprit. So could lung cancer. Finally, they arrived at multiple myeloma, a cancer of the white blood cells—which is what Dave’s cancer turned out to be.
Dave’s friend asked, “Where do you want to be treated in the world, or at least in the United States, so you can get the best possible care?” He added, “Emory Healthcare has one of the very, very top centers in the world for multiple myeloma.”
That’s exactly where Dave went. At Winship Cancer Institute of Emory University, Sagar Lonial, MD, became Dave’s doctor. Lonial is Winship’s chief medical officer, as well as professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine. “His research is one of the reasons that Emory is so world-renowned for multiple myeloma treatment,” says Dave.
For his part, Lonial recalls that Dave’s myeloma had caused significant kidney damage which, at his age, could be a challenge to treat. Dave chose to enroll in a clinical trial using a new antibody that was FDA-approved based on research at Emory University.
A clinical trial can provide access to innovative treatment that may not be available anywhere else. At Winship Cancer Institute, it’s important for patients to have access to clinical trials, and we offer clinical trials for virtually every type of cancer – and at all of our locations. “Combine that with other treatment approaches in the first four months of his treatment,” says Lonial, “and it completely reversed his kidney failure, and he went into a complete remission from a treatment perspective as well.”
Lonial says Dave’s care allowed his providers to prove an idea they had early on — that a three-drug combination would be highly effective for treating his myeloma “in a way that would not just preserve his renal function, but would actually return it back to normal.”